Id: acc0692
Group: 1sens
Protein: KRAS
Gene Symbol: KRAS
Protein Id: P01116
Protein Name: RASK_HUMAN
PTM: prenylation
Site: Cys186
Site Sequence: TPGCVKIKKCIIM--------
Disease Category: Cancer
Disease: Colorectal Cancer
Disease Subtype:
Disease Cellline: Colon-26
Disease Info:
Drug: L-OHP
Drug Info: "L-OHP (Oxaliplatin) is a third-generation platinum-based chemotherapeutic agent primarily used in the treatment of advanced colorectal cancer, often combined with fluorouracil (5-FU) and leucovorin (CF) in regimens such as FOLFOX, where it exerts its anticancer effects by forming DNA cross-links to inhibit replication and transcription. - "
Effect: inhibit
Effect Info: "Simvastatin inhibits KRAS prenylation, thereby enhancing the antitumor effect of L-OHP and increasing the sensitivity of KRAS-mutated colorectal cancer cells to L-OHP."
Note: site unclear
Score: 5.0
Pubmed(PMID): 37069612
Sentence Index:
Sentence:

Sequence & Structure:

MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
KRAS ADAGRASIB GTPase KRas inhibitor 4 - neoplasm ATC
KRAS SOTORASIB GTPase KRas inhibitor 4 - neoplasm ATC
KRAS SOTORASIB GTPase KRas inhibitor 4 - non-small cell lung carcinoma EMA
FDA
KRAS ADAGRASIB GTPase KRas inhibitor 4 - non-small cell lung carcinoma FDA
KRAS SOTORASIB GTPase KRas inhibitor 3 Active, not recruiting non-small cell lung carcinoma ClinicalTrials
KRAS ADAGRASIB GTPase KRas inhibitor 3 Active, not recruiting non-small cell lung carcinoma ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 3 Not yet recruiting metastatic colorectal cancer ClinicalTrials
KRAS ADAGRASIB GTPase KRas inhibitor 3 Active, not recruiting metastatic colorectal cancer ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 3 Active, not recruiting colorectal cancer ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 2 Recruiting neoplasm ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 2 Recruiting ovarian carcinoma ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 2 Active, not recruiting non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 2 Recruiting non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 2 Withdrawn non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 2 Not yet recruiting non-small cell lung carcinoma ClinicalTrials
KRAS ADAGRASIB GTPase KRas inhibitor 2 Recruiting non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 2 Recruiting colorectal cancer ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 2 Recruiting lung cancer ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 1 Active, not recruiting neoplasm ClinicalTrials
ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 1 Recruiting neoplasm ClinicalTrials
ClinicalTrials
KRAS ADAGRASIB GTPase KRas inhibitor 1 Active, not recruiting neoplasm ClinicalTrials
ClinicalTrials
ClinicalTrials
KRAS ADAGRASIB GTPase KRas inhibitor 1 Terminated neoplasm ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 1 Completed liver disease ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 1 Withdrawn pancreatic carcinoma ClinicalTrials
KRAS SOTORASIB GTPase KRas inhibitor 1 Completed non-small cell lung carcinoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 181 P Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 24371225

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: